EULAR rheumatology open
Effect of abatacept on bone in patients with psoriatic arthritis-results from a prospective interventional high-resolution imaging study (ABEPSA)
By Temiz A, Yalcin-Mutlu M, Corte G and 10 others.
Abstract
Objectives
Abatacept (ABA) is a selective costimulation modulator that inhibits T cell activation. It is approved for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). While its efficacy in RA is well established, its effect on structural joint damage in PsA remains uncertain. This study evaluated the effects of ABA on erosive and proliferative bone changes in PsA using high-resolution peripheral quantitative computed tomography (HR-pQCT) over 24 weeks.
Methods
ABA bone effects in PsA with bone biomarkers is a prospective, single-arm, open-label, phase IV trial including patients with active PsA (≥2 swollen/tender joints and ≥1 hand joint erosion at baseline). Participants received weekly subcutaneous ABA (125 mg) for 24 weeks; those with good clinical response at week 12 continued treatment. Bone changes were assessed by HR-pQCT and magnetic resonance imaging (MRI) at baseline and week 24. The primary endpoint was change in erosion volume.